Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Antonelli

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Intensive Care Medicine|June 20, 2018
Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT studyAndrew Conway Morris, Deepankar Datta, Manu Shankar-Hari, et al.
Intensive Care Medicine|October 7, 2018
Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort studyManu Shankar-Hari, Deepankar Datta, Julie Wilson, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Ebiomedicine|February 13, 2022
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and PharmacodynamicsTom M Quinn, Erin E Gaughan, Annya Bruce, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Intensive Care Medicine|June 20, 2018
Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT studyAndrew Conway Morris, Deepankar Datta, Manu Shankar-Hari, et al.
Intensive Care Medicine|October 7, 2018
Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort studyManu Shankar-Hari, Deepankar Datta, Julie Wilson, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Ebiomedicine|February 13, 2022
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and PharmacodynamicsTom M Quinn, Erin E Gaughan, Annya Bruce, et al.
Pageof 2